Belzutifan
| CAS No. | 1672668-24-4 | Cat. No. | BCP32143 |
| Name | Belzutifan | ||
| Synonyms | MK-6482; MK 6482; MK6482; PT2977; PT-2977; PT 2977; | ||
| Formula | C17H12F3NO4S | M. Wt | 383.34 |
| Description | Belzutifan, also known as PT2977 and MK-6482, is HIF-2alpha inhibitor. PT2977 binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis. Belzutifan was approved in 2021 for treatment of von Hippel-Lindau disease under certain conditions | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | HIF | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.